التفاصيل البيبلوغرافية
| العنوان: |
Revisiting Cytomegalovirus Serology in Allogeneic Hematopoietic Cell Transplant Recipients. |
| المؤلفون: |
Portillo, Vera, Masouridi-Levrat, Stavroula, Royston, Léna, Yerly, Sabine, Schibler, Manuel, Mappoura, Maria, Morin, Sarah, Giannotti, Federica, Mamez, Anne-Claire, Delden, Christian van, Chalandon, Yves, Neofytos, Dionysios |
| المصدر: |
Clinical Infectious Diseases; 2/15/2024, Vol. 78 Issue 2, p423-429, 7p |
| مصطلحات موضوعية: |
HOMOGRAFTS, CYTOMEGALOVIRUS diseases, BLOOD plasma, SEROLOGY, COMPARATIVE studies, CELLS, IMMUNITY, DESCRIPTIVE statistics, HEMATOPOIETIC stem cell transplantation, DIAGNOSTIC errors, LONGITUDINAL method, PATIENT safety |
| مستخلص: |
Background Allogeneic hematopoietic cell transplant recipients (allo-HCTRs) with positive cytomegalovirus (CMV) serology may have false-positive results due to blood product transfusion–associated passive immunity. Methods This single-center cohort study included allo-HCTRs with negative baseline (at malignancy diagnosis) CMV serology and indeterminate/low-positive (CMV IgG titer, ≥0.6–<50 U/mL) pretransplant CMV serology with negative pretransplant plasma CMV DNAemia. The CMV status of those patients was reclassified from R+ to R− (CMVR− reclassification group). We compared those patients to allo-HCTRs with negative (CMV IgG titer <0.6 U/mL) pretransplant CMV IgG (CMVR− group). We describe the number and type of patients whose pretransplant CMV status was reclassified from indeterminate/positive to negative. We reviewed all plasma CMV DNAemia tests performed during the first 6 months posttransplant in both groups to assess the safety of this approach. Results Among 246 (84.5%) of 291 transplanted patients identified as CMVR+ pretransplant, 60 (24.4%) were reclassified from CMV serology indeterminate (N:10)/low-positive (N:50) to R−. Only 1 of 60 patients (1.67%) in the CMVR− reclassification group versus 3 of 44 (6.8%; P =.30) in the CMVR− group developed CMV DNAemia during the follow-up period. There were no significant differences in the number of CMV DNAemia tests performed, CMV DNAemia range, and time posttransplant between the 2 groups. Conclusions One of 4 allo-HCT CMVR+ may be falsely flagged as R+, with significant impact on donor selection and prophylaxis administration. A 2-step approach including CMV serology testing at hematologic malignancy diagnosis in allo-HCT candidates and careful review of pretransplant CMV IgG titers may help correctly classify CMV serology status. [ABSTRACT FROM AUTHOR] |
|
Copyright of Clinical Infectious Diseases is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
